Physician

Daniel Richard Douce, M.D.

According to 2025 Medicare claims, Daniel Douce, M.D. (NPI: 1851541353) practices hematology/oncology in the Niles, MI market, with the plurality of this provider's patient population coming from Berrien, MI. This provider's primary affiliated billing organization is LAKELAND MEDICAL PRACTICES (NPI: 1538397120; TIN: 270381199) and primary practice location at 49085-9149. Douce is affiliated with the West Michigan Accountable Care Organization, LLC (ACO ID: A4626), participating under the MSSP model.

Douce's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 427 traditional Medicare patients, billed 1,136 HCPCS/CPT codes, and received $86,775 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 2,961 prescription claims across 493 beneficiaries totaling $5,876,186 in drug costs, led by Revlimid (Lenalidomide). DME data shows 53 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $12,427 to $86,775. Similarly, Part D prescription costs have moved sharply higher in recent years, from $13,647 to $5,876,186. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $10,623 to $341.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	58	119	$12,427
2020	145	566	$49,713
2021	182	650	$67,110
2022	231	739	$57,090
2023	296	788	$55,816
2024	427	1,136	$86,775

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	30	48	$13,647
2020	96	536	$794,459
2021	153	844	$990,912
2022	202	1,358	$1,984,009
2023	289	1,753	$3,351,083
2024	493	2,961	$5,876,186

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	98	$8,561
2016	N/R	45	$3,114
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	14	$2,152
2021	N/R	18	$968
2022	N/R	17	$857
2023	N/R	12	$73
2024	N/R	53	$2,523

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	57	57	$145
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	16	17	$118
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	36	36	$96
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	362	931	$73
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	64	68	$51

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	51	1,358	$865,180
Lenalidomide	Lenalidomide	63	1,652	$752,759
Brukinsa	Zanubrutinib	43	1,290	$577,238
Imbruvica	Ibrutinib	33	942	$488,356
Jakafi	Ruxolitinib Phosphate	36	1,080	$475,683

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	N/R	13	$1,409
J8521	Capecitabine, oral, 500 mg	N	N/R	16	$738
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	13	$226
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	11	$150

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Daniel Richard Douce, M.D.?

Tedicare shows public-source Medicare data for Daniel Richard Douce, M.D. (NPI 1851541353), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Daniel Richard Douce, M.D. have ACO affiliation data?

Daniel Richard Douce, M.D. is shown with ACO affiliation data for West Michigan Accountable Care Organization, LLC (MSSP, ACO ID A4626).

What billing organization is linked to Daniel Richard Douce, M.D.?

Daniel Richard Douce, M.D. is linked to LAKELAND MEDICAL PRACTICES (billing NPI 1538397120) in the available physician profile data.

Does Daniel Richard Douce, M.D. have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.